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The members of the retinoblastoma gene family, Rb/p105,
Rb2/p130 and p107, play a central role in the regulation of cell
cycle progression and differentiation in mammalian cells. In their
active, hypophosphorylated form, these ‘pocket proteins’ bind and
inactivate transcription factors of the E2F family (E2F-1 to E2F-5)
which are important regulators of genes involved in DNA
synthesis and mitosis (Mulligan and Jacks, 1998). The prototype
protein of this family, Rb/p105, forms complexes with E2F-1, -2,
and -3 in the G1 phase of the cell cycle. Phosphorylation of Rb in
late G1 by cyclin-dependent kinases releases E2F transcription
factors and allows progression into S phase (Weinberg, 1995). In
addition to this function, Rb also acts as a transcriptional repressor
which interacts with other transcription factors like c-jun, c/EPB,
SP1, or E2F modulating their repressor or activator function
(Udvadia et al 1993; Mulligan and Jacks, 1998). Somatic muta-
tions of the Rb gene were found in sporadic retinoblastomas, lung
carcinomas, osteosarcomas, breast carcinomas (7–19%) etc.
(Weinberg, 1995). The role of Rb2/p130 in human cancer is less
well studied. Hypophosphorylated Rb2 proteins bind to E2F-4 and
E2F-5 in G0 and early G1 phase of the cell cycle, whereas the
inactive, hyperphosphorylated form predominated in the S phase
(Mulligan and Jacks, 1998). In some experimental systems, Rb2 is
an effective tumour suppressor (Howard et al, 1998; Pupa et al,
1999). Rb2 mutations in human tumours have been found only
sporadically in nasopharyngeal and lung carcinomas (Claudio
et al, 1994, 2000). Rb2 protein expression has been studied in lung
cancer (Baldi et al, 1996; Helin et al, 1997) and oral carcinomas
(Tanaka et al, 1999) showing an inverse correlation with grading in
both tumour types, and in malignant lymphomas, where it was
associated with high levels of the proliferation marker Ki67
(Leoncini et al, 1999). In endometrial carcinomas, Susini et al
(1998) found an association of low Rb2 expression with higher
age, aneuploidy, high grading, and an unfavourable prognosis.
Frequent deletions of chromosome 16q12.2, the locus of the
human Rb2 gene, suggest that Rb2 might also be involved in
mammary carcinomas (Yeung et al, 1993). 
In the present study, we investigated Rb2 protein expression in
68 mammary carcinomas, 4 mammary cell lines, 41 endometrial
carcinomas, and some normal tissue samples by Western blot
experiments, followed by densitometric quantification of band
intensities. In addition, Rb2 mRNA expression was analysed in 35
endometrial and 21 mammary tissue samples. We found associa-
tions of Rb2 expression with Rb and hormone receptors in both
tumour types. Comparison of RT-PCR and Western blot results
and the band pattern observed in immunoblots suggest that 
Rb2 expression might be predominantly regulated at the level of
transcription. 
MATERIALS AND METHODS 
Tissue collection 
All patients were treated at the Hamburg University Hospital,
Dept. of Obstetrics and Gynecology, throughout 1994–1999. All
tissue samples were carefully dissected immediately after surgery
and stored in liquid nitrogen. 
Mammary carcinomas 
We studied tumour specimens from 68 breast cancer patients
(mean age 56.2 years; range 30–85 years) and tumour-free
mammary tissue from 7 patients. Histologically, 51 carcinomas
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were ductal and 12 cases were lobular tumours. In addition, 4
mucinous and 1 medullary carcinoma were analysed. 7 tissue
samples were from recurrences, and 61 from primary tumours. 27
of the primary carcinomas were nodal-negative, whereas 33
tumours were nodal-positive, and nodal involvement is unknown
in one case. The pathological staging of the primary tumours was
done as recommended by the UICC. 12 tumours were classified as
stage 1, 30 cases as stage 2, 4 tumours as stage 3 and 9 tumours as
stage 4, whereas staging data were not available in 6 cases.
According to histological examination, 3 specimens were highly
differentiated (G1), 34 tumors were classified as G2, and 31 cases
were high-grade carcinomas (G3). 
Endometrial carcinomas 
41 endometrial tumours (mean age 64.7 years; range 39–83 years)
and normal endometrial samples from 9 tumour patients were
studied. Among the carcinomas, 14 cases were classified as FIGO
stage 1a, 14 tumours as stage 1b, 5 cases as stage 1c, 3 cases as
stage 2b and 1 tumour as stage 3. In 4 cases, staging data were not
available. Histologically, 28 tumours were of the endometrioid
type. In addition, 5 adenosquamous carcinomas, 1 serous-papillary
tumour, 1 clear cell carcinoma, 2 tumours of mixed differentiation,
2 undifferentiated carcinomas and 2 carcinosarcomas were
analysed. 17 carcinomas were highly differentiated (G1), 14
tumours showed moderate differentiation (G2), and 10 tumours
were poorly differentiated (G3). 
Cell lines 
The mammary carcinoma cell lines T47D (receptor-positive) and
MDA-MB231 (receptor-negative) and the mammary epithelial cell
line HBL-100 were purchased from from ATCC, Rockville, MD
and cultivated as described (Bamberger et al, 1999). The receptor-
positive MCF-7 breast cancer cells were obtained from Dr Fritz
Hölzel, University Clinics of Obstetrics and Gynecology,
Hamburg. 
Western blot analysis 
Protein extraction and Western blots were performed as described
(Bamberger et al, 1999). Frozen tissue was minced and cells were
lysed in ice-cold sample buffer b1 (50 mM Tris pH 6.8, 1% SDS,
and 10% sucrose), and protein concentration was determined
following standard protocols. For electrophoresis, samples were
diluted with a 1:1 mixture of sample buffer b1 and b2 (containing 
50 mM Tris pH 6.8, 3% SDS, 10% sucrose, 10% β -mercap-
toethanol, and 0.01% bromphenol-blue) to a final volume of 100 µ l
and a final protein concentration of 400 µ g ml–1, and heated at 99
˚C for 5 min. Equal amounts of protein (40 µ g) of each tumour
sample were loaded per well, and equal loading was verified by
immunoblotting with actin antibodies. Electrophoresis was
performed in a 6% (Rb2), 8% (Rb, PR), or 10% (ER, actin) poly-
acrylamide separating gel and a 3% stacking gel. Proteins were
transferred to a polyvinylidene difluoride (PVDF) membrane
(Immobilon P, Millipore, Eschborn, Germany). After overnight
incubation at 4 ˚C in blocking solution (0.1 M maleic acid, pH 7.5,
0.15 M NaCl, 0.005% Thimerosal, and 1% blocking reagent,
Boehringer Mannheim, Germany), membranes were incubated for
1 h at room temperature with the following antibodies at the indi-
cated dilutions in 9:1 TBST/blocking solution: rabbit anti-Rb2 
(C-20; Santa Cruz, 1:1000), mouse anti-Rb (G3-245, Pharmingen,
1:400), mouse anti-ER (NCL-ER-6F11, Novocastra, 1:1000),
mouse anti-PR (NCL-PGR, Novocastra, 1:300), goat anti-actin (I-
19, Santa Cruz, 1:10 000). 
After washing, blots were incubated with the second antibody
(peroxidase-conjugated anti-mouse-IgG, 1:2000, peroxidase-con-
jugated anti-rabbit-IgG, 1:5000, or peroxidase-conjugated anti-goat-
IgG, 1:4000, all from Santa Cruz) for 1 h at room temperature. The
second antibodies were visualized by chemiluminescence reagents
(Super Signal West Pico kit, Pierce, Rockfort, Ill.) with Hyperfilm
ECL films (Amersham, Braunschweig, Germany). In parallel
experiments with the same antibody, 20 µ g protein extract from a
positive cell line (T47D or MCF-7) was always loaded in one well
as control for comparable exposition of chemiluminescent
membranes and as standard for densitometry (GS-700 Imaging
Densitometer, BioRad, München, Germany). The intensities of the
specific protein bands were calculated as percent intensity of the
control sample and corrected for equal actin loading. For statistical
analysis, the samples were divided into 2 or 3 groups with similar
band intensities for each antibody. 
Immunohistochemistry 
Ki67 antigen was detected in all mammary and 37 endometrial
tumours with MIB1 monoclonal antibodies (Dianova, Hamburg,
Germany), and the percentage of positive tumour cells was deter-
mined. 
RNA extraction and RT-PCR 
Total RNA was extracted from 100–200 mg tissue specimens with
an RNeasy midi kit (Qiagen, Hilden, Germany). 2.5 µ g total RNA
were transcribed to cDNA using oligo-dT primers and MMLV
reverse transcriptase (Life Technologies, Eggenstein, Germany).
PCR was performed with primers from exon 6 (p130–67F:
CTCACTGGTTTCTAGAACC) and exon 7 (P130-RR: CGTTCA-
GACACCTTGAGAGAG) with an annealing temperature of 59˚C
yielding amplication products of 160 bp. After electrophoresis in
3% agarose gels and ethidium bromide staining, Rb2 mRNA
expression results were evaluated in a semi-quantitative way as
negative, weak, moderate, or strong. As control, a 240 bp fragment
from actin mRNA was amplified as described (Schlott et al., 1997)
which was always positive (Figure 3). Parallel samples without
addition of reverse transcriptase were always negative (not
shown). 
Statistical analysis 
Correlations of the data were examined by χ 2 statistics and
Fisher’s exact test using the SSPS 10.0 software. P values of 0.05
or less were considered statistically significant. 
RESULTS 
Rb2 expression in mammary carcinomas 
Rb2 expression was found in all mammary-derived cell lines
(Figure 1A), with the weakest expression found in T47D cells.
Differences in electrophoretic mobility indicated phosphorylation
of Rb2 proteins in MCF7 and MDA-MB231 cells, whereas T47D
and HBL-100 cells predominantly showed a faster migrating band,548 K Milde-Langosch et al
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probably representing the hypophosphorylated, active form.
Further examination of exponentially growing versus confluent
MDA-MB231 cells showed increased Rb2 expression and the
appearance of 2 bands of higher electrophoretic mobility in
confluent cells (Figure 1B). In the clinical breast cancer samples,
Rb2 protein was detectable in 65/68 (96%) cases under our exper-
imental conditions. For comparison and relative quantification of
Rb2 expression in different tissue samples and for similar exposi-
tion of chemiluminescent membranes, a control sample (MCF7
cell extract) was loaded on each gel. Compared with this 100%-
standard, less than 20% Rb2 expression was found in 16 tumours
(24%), moderate expression (20–50% of control) was observed in
28 cases (41%), whereas more than 50% was found in 24 carci-
nomas (35%). In all Rb2-positive tumour samples, the majority of
Rb2 proteins was found in its faster migrating, hypophosphory-
lated form. In some cases, a second band of minor intensity with
lower electrophoretic mobility was observed (tumors T3, T5, T7,
T61; Figure 1A and B). In the 7 normal mammary tissue samples,
Rb2 expression was low or moderate (mean 12.4% of control,
range 1–33%; Figure 1B). Yet, because of the relatively low
amounts of epithelial cells in these specimens, the results cannot
be correlated with the Rb2 results in the corresponding carci-
nomas. In 2 tumours, a weak 130 kD-band was accompanied by a
second, strongly immunoreactive band at ca 160 kD (see Figure
1A, tumour T6). 
Rb2 expression in endometrial carcinomas 
Using the same cell line as control, Rb2 expression in endometrial
carcinomas was generally lower than in breast cancer samples.
Under the same experimental conditions, Rb2 was undetectable in
12/43 tumours (27%), and less than 20% Rb2 expression of the
control cell line were found in 59% of the carcinomas (Table 2).
As the case number was lower than in mammary tumours, only 2
groups with less than 20% expression or more were compared for
statistical analysis. In normal endometrial tissue samples, Rb2
expression was similar to or weaker than in the corresponding
tumour tissue (mean 22.5% of control, range 5–54%). Similar to
the mammary carcinomas, only a small fraction if any of the Rb2
proteins was found in its hyperphosphorylated, inactive form
(Figure 2). In none of the endometrial tumour samples, aberrant
bands similar to those found in 2 breast cancer samples were
found. 
Correlations of Rb2 expression with prognostic
parameters and Rb expression in mammary
carcinomas 
Correlations with histological and clinical parameters, expression
of the proliferation marker Ki67, steroid hormone receptor status,
and Rb expression are shown in Table 1. 
In mammary carcinomas, reduced Rb2 expression (< 20% of the
standard) was more often found in lobular carcinomas (50% of the
cases) than in the ductal type (18%; Table 1), but the small number
of lobular tumours does not allow reliable correlations. No associ-
ation of Rb2 results with age, clinical stage, nodal involvement,
histological grading or expression of the proliferation marker Ki67
was observed. 
The oestrogen receptor ER was detectable in all but 4 mammary
carcinomas, all normal mammary tissue samples, and the cell lines
T47D and MCF-7 in varying concentrations. ER results had been
evaluated before in a semiquantitative manner as negative, weak,
moderate or strong (Table 1). The progesterone receptor PR was
undetectable under our experimental conditions in 47% (32/68) of
the mammary carcinomas and in the cell lines MDA-MB231 and
HBL-100 with known receptor-negative status. In PR-positive
cases, the receptor was generally expressed in 2 isoforms: the
bigger PR-B which is regarded as the active transcription factor
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Figure 1A Expression of Rb2 and Rb in mammary cell lines and
carcinomas. As loading control, the Rb2 blot was incubated with actin
antibodies. (B) Rb2 expression in MDA-MB231 breast cancer cells in different
states of confluency representing exponentially growing and growth-inhibited
cells (20 µ g protein applied per well). For comparison, one tumour and one
normal mammary tissue sample are shown. 
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Figure 2 Expression of Rb2, Rb, the oestrogen receptor (ER) and the
progesterone receptor isoforms (PR-A, PR-B) in endometrial carcinomas
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Figure 3 Comparison of Rb2 protein expression as determined by Western
blots (top) and Rb2 RNA expression as measured by RT-PCR (bottom) in 10
endometrial carcinomas and the mammary carcinoma cell line MCF7. As
control, Western blot and RT-PCR results for a housekeeping gene are
shown Rb2 expression in breast and endometrial cancer 549
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and the truncated PR-A whose function is not clear (Figure 2). In 5
mammary tumours, only a weak PR-A band without detectable
PR-B expression was found. PR-A and PR-B expression were
analysed separately with T47D cells as control. For statistical
analysis, PR-positive and PR-negative tumours were combined. 
In breast cancer samples, significant correlations of Rb2 with
ER and PR-B expression were found (Table 1), whereas the asso-
ciation with PR-A was not statistically significant. These associa-
tions could not be observed in mammary cell lines: Rb2 expression
was detectable in receptor-positive (T47D, MCF7) and receptor-
negative cells (MDA-MB231, HBL-100) with different elec-
trophoretic mobilities indicating hyperphosphorylation in MCF-7
and MDA-MB231 cells. 
Expression of the retinoblastoma protein Rb was determined with
MCF-7 or MDA-MB231 protein extracts as control. Rb was unde-
tectable in 7/60 breast cancer samples (12%) under our experimental
conditions. There were strong positive correlations of both retinoblas-
toma family members, Rb2 and Rb, in mammary carcinomas (Table
1). In contrast, no significant associations of the retinoblastoma
protein Rb and steroid hormone expression were found (not shown). 
Correlations of Rb2 expression with prognostic
parameters and Rb expression in endometrial
carcinomas 
Rb2 expression in endometrial carcinomas was not associated with
histological type, histological grading, Ki67 staining (Table 2), or
clinical stage (not shown). Reduced Rb2 expression (<20% of
control) was more often found in older than in younger patients
(68% versus 47%; Table 2). However, this difference did not reach
statistical significance. 
The oestrogen receptor ER was detectable in all endometrial
tissue samples in varying intensities, whereas PR was found in
26/41 (63%) of the endometrial tumours. Small contaminations of
normal endometrial tissue which always expresses steroid
hormone receptors might have influenced the results for the
tumours which, therefore, should be regarded with care. With
T47D proteins as 100%-standard, 2 tumour groups of similar size
with less or more than 150% of ER expression were combined for
statistical analysis. For PR-A and PR-B, 2 groups of similar size
with negative/low or stronger PR expression were compared. In
contrast to mammary carcinomas, Rb2 expression was signifi-
cantly associated with PR-B and PR-A, but not to ER expression
in endometrial tumours (Table 2). In addition, there was a strong
positive correlation of Rb2 and Rb. 
Similar to Rb2, expression of the retinoblastoma protein Rb in
endometrial carcinomas correlated significantly with PR-A (P =
0.003) and PR-B (P = 0.019), but to none of the other analysed
parameters (not shown). 
Rb2 mRNA expression in endometrial and mammary
carcinomas 
Rb2 mRNA expression was analysed in a semi-quantitative way
by RT-PCR with RNA derived from 29 endometrial carcinomas,
21 breast cancer samples, 6 normal endometrial tissue samples
from tumour patients, and 3 mammary cell lines (T47D, MDA-
MB231, and HBL-100). In normal endometrium, absent (n = 4),
weak (n = 1), or strong (n = 1) mRNA expression was detected. In
endometrial carcinomas, Rb2 mRNA expression was absent (n =
6), weak (n = 8), moderate (n = 6) or strong (n = 9). Similar to our
Rb2 Western blot results, Rb2 expression on average is higher in
mammary than in endometrial carcinomas with weak (n = 3),
moderate (n = 9) or strong expression (n = 9). There was a good
correlation of Western blot and RT-PCR results in both tumour
types indicating that Rb2 expression is regulated at the level of
transcription in the majority of the tumours (Table 3). 
DISCUSSION 
Our results have shown that loss of Rb2 expression is a frequent
event in endometrial carcinogenesis and correlates significantly
Table 1 Rb2/p130 expression in mammary carcinomas (n = 68).
Associations with histological parameters, hormone receptor status, Rb and
Ki67 expression 
Rb2 expressiona
n < 20% 20–50% > 50%  P
Histological type ductal 51 9 26  16 
lobular 12 6 1 5 
others 5 1 1 3 0.033 
Grading G1–2 37 9 13 15 
G3 31 7 15 9 n.s. 
ER expressionb weak/moderate 31 14 10 7 
strong 37 2 18 17 0.001 
PR-B expressionb negative 37 13 16 8 
positive 31 3 12 16 0.011 
PR-A expressionb negative 32 10 13 9 
positive 36 6 15 15 n.s. 
Rb expressiona <1% 17 11 5 1 
(n = 60) 1–10% 14 2 10 2 
>10% 29 1 9 19 <0.001 
Ki67 expressionc <10% 13 3 5 5 
11–49% 36 7 16 13 
≥ 50% 16 5 5 6 n.s. 
aRelative to MCF7 control cells. bRelative to T47D cells. cPercentage of
positive nuclei in tumour cells (n = 65). 
Table 2 Rb2/p130 expression in endometrial carcinomas (n = 41).
Associations with histological parameters, hormone receptor status, Rb and
Ki67 expression, and age of the patients 
Rb2 expressiona
n < 20% > 20% P
Histological type endometrioid 28 18 10 
others 13 6 7 n.s. 
Grading G1 17 10 7 
G2 14 11 3 
G3 10 3 7 n.s. 
ER expressionb ≤ 150 24 16 8 
>150 17 8 9 n.s. 
PR-B expressionb <1 20 16 4 
>1 21 8 13 0.006 
PR-A expressionb <10 20 17 3 
>10 21 7 14 0.001 
Rb expressiona <10 16 13 3 
>10 25 11 14 0.018 
Ki67 expressionc <50% 21 14 7 
≥ 50% 14 8 6 n.s. 
Age <65 19 9 10 
>65 22 15 7 n.s. 
aRelative to MCF7 control cells. bRelative to T47D cells. cPercentage of
positive nuclei in tumour cells (n = 35).550 K Milde-Langosch et al
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with PR expression in these tumours. Failure of ER/PR expression
is regarded as an important step in advanced endometrial carcino-
genesis and was previously shown to correlate with poor prog-
nosis, and with negative expression of Rb (Li et al, 1996). The close
association of PR and Rb2 expression found by us indicates that loss
of Rb and Rb2 might be involved in tumorigenesis. Decreased Rb2
expression often also coincided with lower ER expression, but this
association did not reach statistical significance. Although this
might be due to a relatively low sample size and heterogeneity of the
group of tumours, our data clearly show that Rb2 expression corre-
lated more strongly with PR-A and PR-B than with ER.
In a multivariate study including p130 expression, grading,
stage, and ploidy of endometrial tumours, low Rb2 expression was
an independent predictor of unfavourable outcome (Susini et al,
1998). Future studies will clarify if Rb2 is an independent prog-
nostic indicator or if this effect is only due to the association with
hormone receptor status. In addition, Rb2 expression was associ-
ated with younger age as shown before (Susini et al, 1998), which
corresponds to the decrease of hormone receptor concentration in
the endometrium with higher age. 
Up to now, less is known about the role of p130/Rb2 in
mammary carcinomas. Compared with endometrial tumours, Rb2
expression in these tumours was higher and showed less variation.
In 2 cases, strong bands of higher molecular weight (see Figure 1,
case T6) might be the result of underlying genetic abnormalities.
In contrast to endometrial carcinomas, Rb2 was not only associ-
ated significantly with Rb and PR, but also with ER. 
Although the mammary gland and the endometrium are both
hormone-responsive, there are differences in the physiological role
of ER and PR in these organs: in endometrial cells, ligand-bound
ER promotes intensive proliferation in the first half of the
menstrual cycle, whereas PR triggers terminal differentiation in
the secretory phase. Endometrial carcinomas are nearly always
ER-positive, but partly PR-negative (Satyaswaroop and
Tabibzadeh, 1997). In mammary epithelial cells, the difference
between ER and PR function is less clear-cut (Miller and Langdon,
1997). The proliferation is only weakly stimulated by ER, and loss
of both receptors is observed during the processes of progression
and dedifferentiation in many tumours. Taken together, Rb2
expression in both tumours is associated with hormone receptors
involved in differentiation processes, namely PR in endometrial
tumours and both ER and PR in mammary carcinomas. 
Previous studies have shown that Rb is not only an important
inhibitor of cell-cycle progression, but also involved in processes
of differentiation (Weinberg, 1995). For Rb2, experimental data
have shown that its expression is a prerequisite of granulocyte
differentiation (Mori et al, 1999) and high Rb2 expression was
found in terminally differentiated cells (Baldi et al, 1997). Our
data support the view that Rb2 is involved in differentiation, at
least in mammary and endometrial cells. 
How can the close correlation of Rb2, Rb and hormone recep-
tors be explained? As far as it is known, oestrogen- and proges-
terone-responsive elements (ERE, PRE) are not involved in the
regulation of Rb and Rb2. A common feature of ER, PR, and Rb is
the ability to interact with jun/fos dimers and activate gene expres-
sion at AP-1 binding sites (Nishitani et al, 1999). In addition, the
expression of ER and Rb is regulated at least partly from AP-1 sites
in their promoter or enhancer regions (Linardopoulos et al, 1993;
Tang et al, 1997). In a previous study, we could show different
patterns of AP-1 proteins in receptor-positive and receptor-negative
mammary carcinomas (Bamberger et al, 1999). Although the
precise mechanism is still unknown, these data suggest that AP-1
transcription factor complexes might be involved in the common
regulation of Rb and hormone receptors, and possibly Rb2. 
Cell-culture experiments revealed the presence of 3 p130 forms
of different phosphorylation states and electrophoretic mobility: 2
faster migrating forms which predominate in G0/G1 and are able
to bind the E2F-4 transcription factor, and 1 slowly migrating,
more phosphorylated, inactive form which is the only detectable
form in the S/G2/M phases of the cell cycle (Mayol et al, 1996).
Similar to these results, one slowly migrating p130 form predomi-
nated in exponentially growing MDA-MB231 breast cancer cells
in our study, whereas 2 additional bands of higher electrophoretic
mobility probably representing the active repressor appeared in
confluent cells. In the tumour tissues analysed in this study, only 2
Rb2 bands can be clearly distinguished, and the faster migrating,
active form predominated in all cases, and in T47D and HBL-100
cells. These results indicate that phosphorylation is not a major way
of Rb2 inactivation in endometrial and mammary carcinogenesis. In
contrast, the corresponding results of protein and mRNA analysis in
most cases indicate that down-regulation of Rb2 in these carcinomas
might take place mainly on a transcriptional level.
Taken together, our results indicate that loss of Rb2 expression
may be associated with the development and dedifferentiation of
most endometrial and a subset of mammary carcinomas. Further
studies will be necessary to clarify the role of p130 down-regula-
tion in carcinogenesis and the interactions of retinoblastoma
proteins and steroid hormone receptors in these tumours. 
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